Comparison of Standard vs. Accelerated Corneal Crosslinking
Recruiting
Phase 2
Phase 3
Interventional Study
Keratoconus
Ectasia Corneal
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Pivotal Trial
This treatment is in the last trial phase before FDA approval.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 10 and older
- Sex
- Any
- Trial phase
- Phase 2/3
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 510 (estimated)
- Sponsor
- Price Vision Group · Industry
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The study objective is to compare accelerated and standard corneal crosslinking for treatment of progressive keratoconus or corneal ectasia.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Documented keratoconus or ectasia after refractive surgery
Exclusion Criteria:
* Insufficient corneal thickness
* Ocular condition that may predispose the eye to complications
* History of chemical injury or delayed epithelial healing
* Condition that would interfere with or…
Contacts